US 10,888,533 B2
Transdermal composition containing donepezil as active ingredient
Young Kweon Choi, Seoul (KR); Dong Hyun Hong, Jeollabuk-do (KR); and Seong Soo Kim, Gyeonggi-do (KR)
Assigned to ICURE PHARMACEUTICAL INC., Seoul (KR)
Filed by ICURE PHARMACEUTICAL INC., Seoul (KR)
Filed on Jun. 16, 2017, as Appl. No. 15/625,054.
Application 15/625,054 is a continuation of application No. PCT/KR2015/013940, filed on Dec. 18, 2015.
Claims priority of application No. 10-2014-0183446 (KR), filed on Dec. 18, 2014.
Prior Publication US 2017/0290780 A1, Oct. 12, 2017
Int. Cl. A61K 9/70 (2006.01); A61K 47/30 (2006.01); A61K 31/445 (2006.01); A61K 31/40 (2006.01)
CPC A61K 9/7084 (2013.01) [A61K 9/70 (2013.01); A61K 31/445 (2013.01); A61K 47/30 (2013.01); A61K 31/40 (2013.01)] 19 Claims
 
1. A transdermal composition containing donepezil as an active ingredient, the transdermal composition comprising:
(a) a backing layer;
(b) a drug-containing matrix layer comprising, based on a total weight of the drug-containing matrix layer,
(b-1) 15-55 wt % of donepezil or a pharmaceutically acceptable salt thereof,
(b-2) 25-70 wt % of an EVA-based adhesive,
(b-3) 5-20 wt % of at least one selected from the group consisting of a pyrrolidone derivative and a C8-18 aliphatic derivative, and
(b-4) 1-10 wt % of triacetin or a citric acid derivative,
(c) a polymer adhesive matrix layer comprising, based on a total weight of the polymer adhesive matrix layer, 60 wt % or more of an acrylic adhesive, wherein the acrylic adhesive does not contain a functional group; and
(d) a release layer;
wherein the EVA-based adhesive is an ethylene vinyl acetate (EVA) copolymer; and
wherein the polymer adhesive matrix layer excludes donepezil or a pharmaceutically acceptable salt thereof.